Meeting
2017 Gastrointestinal Cancers Symposium
Outcomes of second line treatment in patients with advanced and metastatic biliary cancers.
Authors
Gustavo Figueiredo Marcondes Westin
Mayo Clinic, Rochester, MN
Gustavo Figueiredo Marcondes Westin , Samer Alsidawi , Chandrikha Chandrasekharan , Andrew M. Briggler , Brendon Huffman , Angeline Pallante , Joleen Marie Hubbard , Steven R. Alberts , Thorvardur Ragnar Halfdanarson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 420)
DOI
10.1200/JCO.2017.35.4_suppl.420
Abstract #
420
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).
First Author: Grainne M. O'Kane
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer
Poster
2018 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – the RAMIRIS Study.
First Author: Sylvie Lorenzen
Poster
2016 Gastrointestinal Cancers Symposium
Long-term responders to palliative chemotherapy for advanced biliary tract cancer.
First Author: Mark Doherty